Next-Generation Antibody Therapeutics Market with COVID-19 Impact Analysis, By Therapeutic Area (Oncology, Autoimmune/Inflammatory), By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins, Biosimilar Antibody Products), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Next-Generation Antibody Therapeutics Market size was valued at USD 5,007.1 million in 2022, expanding at a CAGR of 10.3% from 2023 to 2030.
Next-generation antibody therapeutics refer to a class of advanced therapeutic agents that harness the specificity and versatility of antibodies to treat various diseases. These therapeutics are designed to overcome limitations of conventional monoclonal antibodies (mAbs) and offer improved efficacy, enhanced selectivity, and expanded therapeutic potential. They are engineered using innovative technologies to optimize their binding affinity, functional properties, and therapeutic capabilities. Next-generation antibody therapeutics include various formats, such as bispecific antibodies, antibody-drug conjugates (ADCs), and antibody fragments. Bispecific antibodies can simultaneously target two different antigens, allowing for novel treatment strategies. ADCs combine an antibody with a cytotoxic payload, enabling targeted delivery of potent anticancer agents. Antibody fragments, such as single-domain antibodies and antibody mimetics, offer improved tissue penetration and modularity for diverse applications.
Next-Generation Antibody Therapeutics Market- Market Dynamics
Next-generation antibody therapeutics hold significant promise in the treatment of chronic diseases. Several chronic diseases have seen a rise in their prevalence in recent years, including cardiovascular diseases, diabetes, cancer, autoimmune disorders, neurodegenerative diseases, and respiratory conditions, among others. According to the world health organization, Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. The development of next-generation antibody therapeutics is driven by the need for more effective and targeted treatment options in various disease areas. Traditional monoclonal antibodies (mAbs) have limitations in terms of selectivity, potency, and overcoming resistance mechanisms. This has led to the exploration and advancement of next-generation antibody therapeutics.
One key driver is the increasing understanding of disease biology and the identification of new therapeutic targets. Next-generation antibodies can be engineered to specifically bind to these targets, allowing for more precise and personalized treatment approaches. The advancements in antibody engineering and protein design technologies have also facilitated the development of novel formats, such as bispecific antibodies and antibody-drug conjugates, which provide enhanced therapeutic potential. The development and adoption of next-generation antibody therapeutics face certain restraints, including complex manufacturing processes, high costs, and regulatory challenges. The need for rigorous safety and efficacy assessments, as well as competition from established therapies, can also restrain their widespread implementation in clinical practice.
Next-Generation Antibody Therapeutics Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is anticipated to dominate the growth of the next-generation antibody therapeutics market, due to the rise in auto-immune diseases, and increased healthcare expenditure. Next-generation antibody therapeutics show significant promise in the treatment of autoimmune diseases by offering targeted and specific interventions. North America has exhibited a significant demand for next-generation antibody therapeutics, driven by several factors. The region's advanced healthcare infrastructure, robust research and development capabilities, and high prevalence of complex diseases contribute to the demand for innovative treatment options. Moreover, North America has a strong pharmaceutical and biotechnology industry, which fosters the development and commercialization of next-generation antibody therapeutics. The region's regulatory environment, including the U.S. FDA's accelerated approval pathways for breakthrough therapies, encourages the adoption of novel treatments. Additionally, the growing emphasis on precision medicine and targeted therapies in North America further fuels the demand for next-generation antibody therapeutics with their potential for improved efficacy and patient outcomes.
Next-Generation Antibody Therapeutics Market- Competitive Landscape:
The competitive landscape of next-generation antibody therapeutics is characterized by a dynamic and rapidly evolving market. Numerous pharmaceutical and biotechnology companies, both established players and emerging startups, are actively involved in research, development, and commercialization of these therapeutics. Key players in the field include large biopharmaceutical companies with extensive antibody expertise, as well as specialized companies focusing on antibody engineering and innovation. Collaboration and partnerships between industry leaders and academic institutions are common to leverage complementary expertise and resources. The competition is driven by the race to develop novel formats, enhance target specificity, improve manufacturing processes, and secure intellectual property rights to gain a competitive edge in the market. Numerous companies and research institutions are actively involved in the development and commercsialization of these innovative therapies. For instance, on January, 2022, Amgen and Generate Biomedicines nowadays announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET KEY PLAYERS
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax CorpC
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA
- Oncology
- Autoimmune/Inflammatory
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TECHNOLOGY
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Fc-engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Next-Generation Antibody Therapeutics Market Overview
1.1. Study Scope
2. Executive Summary
2.1. Market Snippet
2.1.1. Next-Generation Antibody Therapeutics Market Snippet by Therapeutic Area
2.1.2. Next-Generation Antibody Therapeutics Market Snippet by Technology
2.1.3. Next-Generation Antibody Therapeutics Market Snippet by Country
2.1.4. Next-Generation Antibody Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Next-Generation Antibody Therapeutics Key Market Trends
3.1. Next-Generation Antibody Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Next-Generation Antibody Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Next-Generation Antibody Therapeutics Market Opportunities
3.4. Next-Generation Antibody Therapeutics Market Future Trends
4. Next-Generation Antibody Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Next-Generation Antibody Therapeutics Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Next-Generation Antibody Therapeutics Market Landscape
6.1. Next-Generation Antibody Therapeutics Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Next-Generation Antibody Therapeutics Market – By Therapeutic Area
7.1. Overview
7.1.1. Segment Share Analysis, By Therapeutic Area, 2022 & 2030 (%)
7.1.2. Oncology
7.1.3. Autoimmune/Inflammatory
8. Next-Generation Antibody Therapeutics Market – By Technology
8.1. Overview
8.1.1. Segment Share Analysis, By Technology, 2022 & 2030 (%)
8.1.2. Antibody-Drug Conjugates (ADCs)
8.1.3. Bispecific Antibodies
8.1.4. Fc-engineered Antibodies
8.1.5. Antibody Fragments and Antibody-like Proteins
8.1.6. Biosimilar Antibody Products
9. Next-Generation Antibody Therapeutics Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
9.2. North America
9.2.1. Overview
9.2.2. Next-Generation Antibody Therapeutics Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.2.4. North America Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.2.5. North America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Next-Generation Antibody Therapeutics Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.7. Italy
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.7.3. Italy Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.7.4. Italy Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.8. United Kingdom
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.8.3. United Kingdom Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.8.4. United Kingdom Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.9. France
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.9.3. France Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.9.4. France Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.10. Russia
9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.10.2. Russia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.10.3. Russia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.11. Netherlands
9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.11.2. Netherlands Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.11.3. Netherlands Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.12. Sweden
9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.12.2. Sweden Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.12.3. Sweden Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.13. Poland
9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.13.2. Poland Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.13.3. Poland Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.3.14. Rest of Europe
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.3.14.4. Rest of the Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Next-Generation Antibody Therapeutics Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.6. India
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.6.3. India Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.6.4. India Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.7.3. China Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.7.4. China Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.8.3. Japan Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.8.4. Japan Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.9.3. South Korea Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.9.4. South Korea Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.11. Thailand
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.11.3. Thailand Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.11.4. Thailand Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.12. Indonesia
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.12.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.12.4. Indonesia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Next-Generation Antibody Therapeutics Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.5.5. Latin America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Next-Generation Antibody Therapeutics Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.7. United Arab Emirates
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.7.4. United Arab Emirates Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
10. Key Vendor Analysis- Next-Generation Antibody Therapeutics Industry
10.1. Competitive Dashboard
10.2. Company Profiles
10.2.1. Pfizer
10.2.2. Roche
10.2.3. Bristol-Myers Squibb
10.2.4. Amgen
10.2.5. AstraZeneca
10.2.6. Bayer
10.2.7. Takeda Pharmaceuticals
10.2.8. Biogen
10.2.9. Seattle Genetics
10.2.10. ImmunoGen
10.2.11. Kyowa Hakko Kirin
10.2.12. Xencor
10.2.13. Dyax CorpC
11. 360 Degree Analyst View
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
